Vaxart, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Vaxart, Inc. (VXRT) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price of $2.30 per share as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice · last filed 2026-08-06
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $2.30.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $2.59.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $2.84.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $2.88.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $2.30 10-Q · filed 2026-08-06 |
| 2026-03-31 | $2.59 S-1 · filed 2026-05-08 |
| 2025-12-31 | $2.84 S-1 · filed 2026-05-08 |
| 2025-09-30 | $2.88 10-Q · filed 2025-11-13 |
| 2025-06-30 | $2.85 10-Q · filed 2025-08-13 |
| 2025-03-31 | $2.94 10-Q · filed 2025-05-13 |
| 2024-12-31 | $3.08 10-K · filed 2025-03-20 |
| 2024-09-30 | $3.02 10-Q · filed 2024-11-13 |
| 2024-06-30 | $2.98 10-Q · filed 2024-08-08 |
| 2024-03-31 | $3.02 10-Q · filed 2024-05-13 |
| 2023-12-31 | $3.17 10-K · filed 2024-03-14 |
| 2023-09-30 | $4.08 10-Q · filed 2023-11-02 |
| 2023-06-30 | $4.05 10-Q · filed 2023-08-03 |
| 2022-09-30 | $3.75 10-Q · filed 2022-11-09 |
| 2022-06-30 | $3.33 10-Q · filed 2022-08-08 |
| 2022-03-31 | $3.13 10-Q · filed 2022-05-09 |
| 2021-12-31 | $4.85 10-K · filed 2022-02-24 |
| 2021-09-30 | $2.67 10-Q · filed 2021-11-04 |
| 2021-06-30 | $2.52 10-Q · filed 2021-08-05 |
| 2021-03-31 | $2.65 10-Q · filed 2021-05-06 |
| 2020-12-31 | $2.68 10-K · filed 2021-02-25 |
| 2020-09-30 | $2.79 10-Q · filed 2020-11-12 |
| 2020-06-30 | $3.22 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |